TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02048319

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pasireotide LAR 60 mg
Description: Pasireotide long acting release, intramuscular injection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Aspiration sclerotherapy
Description: Percutaneous drainage of the hepatic cyst with subsequent ethanol instillation

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Aspiration sclerotherapy
Description: Percutaneous drainage of the hepatic cyst with subsequent ethanol instillation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline solution, injected as placebo
Study: NCT02888938

Intervention type: OTHER
Intervention: pelvic radiography

Intervention type: OTHER
Intervention: pelvic MRI

Intervention type: OTHER
Intervention: pelvic CT-scan
Study: NCT04692636

Intervention type: DIAGNOSTIC_TEST
Intervention: Measure: BP measurements, inter-dialysis BP variability, intra-dialysis hypotension
Description: BP will be measured at the beginning and end of each dialysis session in a seated position by a trained dialysis nurse in accordance with the routine unit practice and entered into an electronic database. BP was measured using validated oscillometric BP monitor equipped in hemodialysis machines (Fresenius 4008S or Nikisso DBB-05), which were maintained as per dialysis unit protocols.
Study: NCT00097604

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Valerian root extract
Description: Valerian root extract, 100 mg softgels, 3 softgels each night for 2 weeks, 30 minutes before bedtime

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Valerian root extract
Description: Valerian root extract, 100 mg softgels, 3 softgels each night for 2 weeks, 30 minutes before bedtime
Study: NCT02194465

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2623091
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2623091
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tadalafil
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tadalafil
Description: Administered orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Spironolactone
Description: Administered orally
Study: NCT01630538

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide 1.5 mg/kg orally daily for 180 days adjusted for renal function
Study: NCT02618499

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Timing of administration of post partum Oxytocin
Description: 10 IU of oxytocin given IV at different times after birth

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Timing of administration of post partum Oxytocin
Description: 10 IU of oxytocin given IV at different times after birth
Study: NCT02194465

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered orally
Study: NCT03647852

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: 1.methylprednisolone pulse (15-30mg/kg/d) for 3 days with continued oral prednisolone(2mg/kg/d) 2.if the patients still complain abdominal pain and feel abdominal tenderness on the third day after intervention , patients would be given IVIG(2g/kg/d)as a change

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IVIG
Description: 1. IVIG 2g/kg and oral prednisolone 2mg/kg/d 2.if the patients still complain abdominal pain and feel abdominal tenderness on the third day after intervention , patients would be given methylprednisolone pulse (15-30mg/kg/d) for 3 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: other basic supportive treatment
Description: 1. Omeprazole 0.8mg/kg.d.The maximum dose is less than 40mg per day~2. Low molecular weight heparin calcium 50IU/kg.d

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: other basic supportive treatment
Description: 1. Omeprazole 0.8mg/kg.d.The maximum dose is less than 40mg per day~2. Low molecular weight heparin calcium 50IU/kg.d
Study: NCT02194465

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally
Study: NCT02451384

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: routine surgery
Description: To observe if the surgeries can influence the countings of circulating tumor cells of the patients.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: no-touch surgery
Study: NCT03300765

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: Apatinib will be used as induction therapy in experimental arm.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity modulated radiation therapy
Description: Intensity modulated radiation therapy will be used for patients with progression disease during induction therapy or after induction therapy.
Study: NCT02633774

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propafenone
Description: AAD(antiarrhythmic drug)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Apixaban
Description: anti-coagulation
Study: NCT00761319

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Travoprost ophthalmic solution 0.004% with SofZia® preservative system (TRAVATAN Z®)
Description: Ophthalmic solution for the treatment of open-angle glaucoma or ocular hypertension, one drop a day, dosed topically for 90 days. Referred to as travoprost.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Latanoprost ophthalmic solution 0.005% (XALATAN®)
Description: Ophthalmic solution for the treatment of open-angle glaucoma or ocular hypertension, one drop a day, dosed topically for 90 days. Referred to as latanoprost.
Study: NCT02451384

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laparoscopic surgery
Study: NCT03272776

Intervention type: DEVICE
Intervention: Protector Laryngeal Mask airway
Description: Evaluate the time of insertion, performance, security and insertion success rate of the Protector Laryngeal Mask in patients under general anasthesia.
Study: NCT02032238

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: laser photocoagulation
Description: Standard bevacizumab Injections will be combined with laser photocoagulation in a pre-defined manner
Study: NCT04655170

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Revefenacin (YUPELRI) & Formoterol (Perforomist)
Description: Revefenacin is a Long-acting anticholinergics (LAMAs) and Formoterol is Long-acting bronchodilators, beta-agonists (LABAs).
Study: NCT02474836

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Skin Prick Test - Atopic subjects
Description: Skin prick test of 4 concentrations of each allergenic source, together with a positive and negative control, using 10 mg/ml histamine dihydrochloride solution and a glycerinated phenol saline solution, respectively, will be tested in every patient in duplicate on the volar surface of the forearm. Assessment of the wheal size after 15 minutes.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Skin Prick Test - Non Atopic subjects
Description: Skin prick test of 4 concentrations of each allergenic source, together with a positive and negative control, using 10 mg/ml histamine dihydrochloride solution and a glycerinated phenol saline solution, respectively, will be tested in every subjects in duplicate on the volar surface of the forearm. Assessment of the wheal size after 15 minutes.

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Skin Prick Test - Allergic subjects
Description: Skin prick test of 4 concentrations of each allergenic source, together with a positive and negative control, using 10 mg/ml histamine dihydrochloride solution and a glycerinated phenol saline solution, respectively, will be tested in every patient in duplicate on the volar surface of the forearm. Assessment of the wheal size after 15 minutes.
Study: NCT01373164

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Galunisertib
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Galunisertib
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Galunisertib
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Galunisertib
Description: Administered orally
Study: NCT04655170

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Albuterol Inhalation Aerosol (short-acting beta-agonists) & Ipratropium Aerosol (short-acting anticholinergic)
Description: Albuterol Inhalation Aerosol (short-acting beta-agonists) \& Ipratropium Aerosol (short-acting anticholinergic)
Study: NCT01373164

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Administered intravenously
Study: NCT01783691

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NKTT120
Study: NCT01373164

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Administered intravenously
Study: NCT03043105

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thalidomide, cyclophosphamide and prednisone
Description: * Thalidomide: 100mg QN for 1 year; And maintained with 100mg QN for the second year;~* Cyclophosphamide: 300mg/m2 on Day 1, 8, 15, 22 every month for 1 year;~* Prednisone: 1mg/kg on Day 1-2, 8-9, 15-16, 22-23 every month for 1 year.
Study: NCT01373164

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered orally
Study: NCT01443884

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Grape powder, followed by placebo powder
Description: For three weeks, twice per day, volunteers will consume one packet of freeze-dried grape powder containing the equivalent of approximately 2 servings of fresh grapes (46 grams of powder) stirred into water. Following a two week washout, volunteers will consume one packet of placebo powder twice per day for three weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo powder followed by grape powder
Description: For three weeks, twice per day, volunteers will consume one packet of placebo powder stirred into water. Following a two week washout, volunteers will consume one packet of freeze-dried grape powder containing the equivalent of approximately 2 servings of fresh grapes (46 grams of powder) twice per day for three weeks.
Study: NCT01570764

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Prednisone 15 mg/d + monthly pulse cyclophosphamide 700 mg/m ² diminished to 600 mg/m ² in patients over 65 years or having a creatinine clearance lower than 30 ml/min for 12 months.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Prednisone 15 mg/d + monthly pulse of placebo of cyclophosphamide. The posology and the methods of administration of the placebo of cyclophosphamide (NaCl) will be the same as those used for cyclophosphamide
Study: NCT04512495

Intervention type: OTHER
Group type: OTHER
Intervention: Blood samples will be collected at two times :
Description: * at Baseline,~* after surgery or at the time of post-chemotherapy evaluation.
Study: NCT00743106

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fenoldopam
Description: Fenoldopam (0.1 \~g/kg/min)started during surgery and lasting for a total of 24 hours

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo infusion(0.9% Nacl) beginning during surgery and lasting for up 24 hours post surgery
Study: NCT03497013

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active tDCS
Description: All patients received 2-mA anodal left/cathodal right prefrontal tDCS treatment (fifteen 30-minutes sessions: Monday to Friday once daily, every other week to do a group of treatment).

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham tDCS
Description: For sham stimulation, the device was set to turn off after 30 seconds(study model).
Study: NCT03892278

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Water-based aerobic training
Description: Participants who will be randomized for the intervention in the aerobic training group will carry out exercises with no interval for exercise change. Intensity will be increased every mesocycle and participants will carry out three 3-minute series of each exercise. In the first mesocycle (weeks 1-2) the intensity will correspond to 80-85% of heart rate corresponding to the anaerobic threshold (HRat). In the second mesocycle (weeks 3-4) the intensity will correspond to 85-90% of HRat. In the third mesocycle, the intensity will correspond to 90-95% of HRat from weeks 5-7. In the fourth mesocycle, the intensity will correspond to 95-100% of HRat from weeks 8-10. In the fifth mesocycle (weeks 11-13) the intensity will correspond to the 100-105% of HRat for 2 minutes and \<85% of HRat for 1 minute. The last mesocycle (weeks 14-16) the intensity will correspond to the 105-110% of HRat for 2 minutes and \<85% of HRat for 1 minute.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Water-based aerobic and combined training
Description: Participants who will be randomized for the intervention in the aerobic and combined training group will perform 8 weeks of aerobic training and more 8 weeks of aerobic and resistance training in same session. In aerobic training the participants will perform three 3-min series of each exercise. The intensity will correspond to 80-85% of heart rate of anaerobic threshold (HRat) (weeks 1-2), 85-90% of HRat (weeks 3-4), 90-95% of HRat (weeks 5-7), 95-100% of HRat (weeks 8-10), 100-105% for 2 min and \<85% of HRat for 1 min (weeks 11-13) and 105-110% for 2 min and \<85% of HRat for 1 min (weeks 14-16). Resistance training will be divide into two blocks of exercises perform each repetition at maximal effort, speed and amplitude. Participants will perform 2 sets of 30 s for each block in the first mesocycle (weeks 9-10), 3 sets of 20 s in the second mesocycle (weeks 11-13) and 4 sets of 15 s in the third mesocycle (weeks 14-16).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: The control group will perform a weekly session composed of 30 minutes of therapeutic and playfull exercises in the aquatic environment, involving games, relaxation, massage and conversation.The participants will receive instructions to perform the movements as slowly as possible to avoid physical effort.
Study: NCT00799214

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 gram emollient cream to be inserted intravaginally qhs (once before bed) for 10 days or less if intolerable side effects occur.
Study: NCT02037087

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Good household prenatal practice
Description: Knowledge on nutrition, labor, non-medical pain management, breastfeeding and depression

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Care seeking
Description: * Danger-sign recognition~* Reminders for government projects
Study: NCT00799214

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Boric acid
Description: Boric acid = 600 mg boric acid compounded in emollient cream (1 gram total) to be inserted intravaginally qhs (once before bed) for 10 days or less if intolerable side effects occur.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metronidazole
Description: Metronidazole = 10 % intravaginal cream (Sanofi-Aventis Canada Inc Product DIN 01926861) (for a total of 37.5 mg metronidazole) to be inserted intravaginally qhs (once before bed) for 10 days or less if intolerable side effects occur.
Study: NCT02327663

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emtricitabine
Description: emtricitabine were given to each patients at baseline and respoonse guided therapy was adopted according HBV DNA level at week 24

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emtricitabine
Description: emtricitabine were given to each patients at baseline and respoonse guided therapy was adopted according HBV DNA level at week 24
Study: NCT00029146

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: extracranial-intracranial bypass surgery
Description: Surgical anastomosis of a superficial temporal artery branch to a middle cerebral artery branch through a small craniectomy plus best current practice medical therapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: best medical therapy
Description: best current practice medical therapy
Study: NCT01640834

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2409021
Description: Administered orally
Study: NCT02037087

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Full bank of SMS
Description: * Danger-sign recognition~* Reminders for government projects~* Knowledge on nutrition, labor, non-medical pain management, breastfeeding and depression
Study: NCT03738696

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exparel
Description: A long-acting injectable sodium channel blocker bound to lipid that is indicated in controlling postoperative pain

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: A short-acting injectable sodium channel blocker bound to lipid that is indicated in controlling postoperative pain
Study: NCT01640834

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2409021
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally
Study: NCT02049203

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ataciguat

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01640834

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucagon
Description: Administered via intramuscular injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucagon
Description: Administered via intramuscular injection
Study: NCT03445429

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 3D-display system
Description: The subjects will perform tasks on a minimal-invasive/laparoscopic training set-up. They will perform the tasks with a 3D-display system or a 4K-display system. The intervention type 3D-display system means that the training-set up is performed first with 3D-display system an after that with the 4K-display system.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 4K-display system
Description: The subjects will perform tasks on a minimal-invasive/laparoscopic training set-up. They will perform the tasks with a 3D-display system or a 4K-display system. The intervention type 4K-display system means that the training-set up is performed first with 4K-display system and after that with the 3D-display system.
Study: NCT02741284

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Room air

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 10L Oxygen by nonrebreather mask
Study: NCT02705430

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: EPA and DHA capsules of 2 g/day
Description: EPA and DHA capsules of 2 g/day

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stress management phone application (Eco Fusion Mentally)
Description: Stress management phone application (Eco Fusion Mentally)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: life style program using a mobile phone (Eco Mentally and NewMe)
Description: life style program using a mobile phone (Eco Mentally and NewMe)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: life style program using a mobile phone (Eco Mentally and NewMe)
Description: life style program using a mobile phone (Eco Mentally and NewMe)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: mobile phone
Description: mobile phone

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: mobile phone
Description: mobile phone
Study: NCT01640834

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Glucagon
Description: Administered via intramuscular injection
Study: NCT02326480

Intervention type: OTHER
Intervention: Identification of genetic causes of obesity
Description: A blood test will be performed to the child and his/her parents with the aim of identifying genetic causes of obesity. Different analysis will be as follows: caryotypes, Raindance, whole exome, in order to find potential mutations or new genes associated to this condition

Intervention type: OTHER
Intervention: Identification of genetic causes of obesity
Description: A blood test will be performed to the child and his/her parents with the aim of identifying genetic causes of obesity. Different analysis will be as follows: caryotypes, Raindance, whole exome, in order to find potential mutations or new genes associated to this condition
Study: NCT04179292

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hand Therapy by Physiotherapist
Description: stretching exercises; all finger joints, wrist and supination-pronation direction strengthening exercises; finger and wrist functional exercises retrograde massage; starting from the distal phalanx to the elbow sensory education; desentilation training (cotton...) breathing exercises 5 days / week, 8 weeks in total~* 3 days / week with physiotherapist~* 2 days / week as home program 30 minutes / day 12 repetitions
Study: NCT02705430

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: mobile phone
Description: mobile phone
Study: NCT04179292

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hand Therapy as home program
Description: stretching exercises; all finger joints, wrist and supination-pronation direction strengthening exercises; finger and wrist functional exercises retrograde massage; starting from the distal phalanx to the elbow sensory education; desentilation training (cotton...) breathing exercises 5 days / week, 8 weeks in total~* 3 days / week with physiotherapist~* 2 days / week as home program 30 minutes / day 12 repetitions
Study: NCT02352285

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolvaptan
Description: Start with 15mg to titrate upwards to 30mg to 60mg, once a daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Start with 15mg to titrate upwards to 30mg to 60mg, once a daily